Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Veröffentlicht vonadmin

Tran, B; Horvath, L; Dorff, TB; Greil, R; Machiels, JPH; Roncolato, F; Autio, KA; Rettig, M; Fizazi, K; Lolkema, MP; Fermin, AC; Salvati, M; Kouros-Mehr, H

View this publication in the PUBMED database